Travere Therapeutics (TVTX) Current Deferred Revenue (2021 - 2024)
Travere Therapeutics' (TVTX) quarterly Current Deferred Revenue came in at $2.8 million in Q4 2024, down 68.48% YoY from $8.9 million in Q1 2024, and down 25.9% on a QoQ basis from $3.8 million in Q3 2024.
Travere Therapeutics (TVTX) Current Deferred Revenue (2021 - 2024) Analysis & Trends
Travere Therapeutics (TVTX) has 4 years of Current Deferred Revenue data on file, last reported at $2.8 million in Q4 2024.
- Quarterly Current Deferred Revenue fell 68.48% year-over-year to $2.8 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.8 million (down 68.48% YoY) and the FY2024 annual result came in at $2.8 million, down 68.48% from the prior year.
- Current Deferred Revenue slipped to $2.8 million in Q4 2024, from $3.8 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $43.0 million in Q3 2021 to a low of $2.8 million in Q4 2024.
- A 4-year average of $14.2 million and a median of $10.6 million in 2023 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue plunged 73.53% — and 2023, when it retreated 18.07%.
- Tracing TVTX's Current Deferred Revenue over 4 years: stood at $36.6 million in 2021, then sank by 37.49% to $22.9 million in 2022, then plunged by 61.01% to $8.9 million in 2023, then tumbled by 68.48% to $2.8 million in 2024.
- The last three Current Deferred Revenue figures came in at $2.8 million (Q4 2024), $3.8 million (Q3 2024), and $5.4 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.82 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Jun 30, 2024 | 5.38 Mn |
| Mar 31, 2024 | 6.46 Mn |
| Dec 31, 2023 | 8.93 Mn |
| Sep 30, 2023 | 8.96 Mn |
| Jun 30, 2023 | 10.24 Mn |
| Mar 31, 2023 | 10.98 Mn |
| Dec 31, 2022 | 22.91 Mn |
| Sep 30, 2022 | 11.38 Mn |
| Jun 30, 2022 | 12.50 Mn |
| Mar 31, 2022 | 14.23 Mn |
| Dec 31, 2021 | 36.65 Mn |
| Sep 30, 2021 | 43.00 Mn |